uniQure (NASDAQ:QURE) CEO Sells $26,079.34 in Stock

uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

uniQure Trading Down 3.8 %

Shares of QURE opened at $15.06 on Friday. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $17.39. The firm’s 50-day simple moving average is $6.85 and its two-hundred day simple moving average is $6.28. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The firm had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. Sell-side analysts forecast that uniQure will post -3.81 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on QURE. StockNews.com upgraded uniQure to a “sell” rating in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of uniQure in a research report on Tuesday. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $20.00 to $52.00 in a research note on Tuesday. Guggenheim reissued a “buy” rating on shares of uniQure in a research note on Wednesday. Finally, Wells Fargo & Company raised uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, two have given a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.14.

Institutional Investors Weigh In On uniQure

A number of institutional investors have recently modified their holdings of the stock. RTW Investments LP purchased a new position in shares of uniQure in the 3rd quarter worth about $49,000. China Universal Asset Management Co. Ltd. grew its position in uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares during the last quarter. Atria Investments Inc bought a new stake in uniQure during the 3rd quarter valued at about $53,000. Quarry LP purchased a new position in uniQure in the third quarter worth about $58,000. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,306 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.